Patents by Inventor Thomas P. Maduskuie

Thomas P. Maduskuie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20110224157
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: March 30, 2011
    Publication date: September 15, 2011
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravi Kumar Jalluri, Jordan S. Fridman, Krishna Vaddi
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20100240671
    Abstract: The present invention relates to substituted heterocyclic compounds of Formula I or XI: or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine II4 receptor inhibitors useful in the treatment of histamine II4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.
    Type: Application
    Filed: March 19, 2010
    Publication date: September 23, 2010
    Applicant: INCYTE CORPORATION
    Inventors: Jincong ZHUO, Thomas P. MADUSKUIE, Ding-quan QIAN, Wenqing YAO
  • HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20100022522
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: August 27, 2009
    Publication date: January 28, 2010
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravikumar Jalluri, Jordan S. Fridman, Krishna Vaddi
  • TETRACYCLIC INHIBITORS OF JANUS KINASES
    Publication number: 20090215766
    Abstract: The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.
    Type: Application
    Filed: August 6, 2008
    Publication date: August 27, 2009
    Inventors: James D. Rodgers, Darius J. Robinson, Argyrios G. Arvanitis, Thomas P. Maduskuie, JR., Stacey Shepard, Louis Storace, Haisheng Wang, Maria Rafalski, Ravi Kumar Jalluri, Andrew P. Combs, Matthew L. Crawley
  • HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20090181959
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: June 12, 2008
    Publication date: July 16, 2009
    Applicant: INCYTE CORPORATION
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravi Kumar Jalluri, Jordan S. Fridman, Krishna Vaddi
  • Succinoylamino lactams as inhibitors of a-? protein production
    Patent number: 7507815
    Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: March 24, 2009
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
  • SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION
    Publication number: 20080293692
    Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
    Type: Application
    Filed: December 4, 2007
    Publication date: November 27, 2008
    Applicant: BRISTOL-MYERS SQUIBB PHARMA COMPANY
    Inventors: Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
  • Succinoylamino lactams as inhibitors of A? protein production
    Patent number: 7304055
    Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: December 4, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
  • Succinoylamino lactams as inhibitors of A? protein production
    Patent number: 7304056
    Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: December 4, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
  • Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme
    Patent number: 7125870
    Abstract: The present application describes novel isoxazoline of formula I or II: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), or a combination thereof.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: October 24, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chu-Biao Xue, Thomas P. Maduskuie, Stephen E. Mercer
  • Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme
    Patent number: 7102008
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP) and/or TNF-? converting enzyme (TACE), or a combination thereof.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: September 5, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: Thomas P. Maduskuie
  • Succinoylamino lactams as inhibitors of A-? protein production
    Patent number: 7101870
    Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: September 5, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
  • Uracil derivatives as inhibitors of TNF-? converting enzyme (TACE) and matrix metalloproteinases
    Patent number: 7101883
    Abstract: The present application describes novel uracil derivatives of formula I: A-W-U-X-Y-Z-Ua-Xa-Ya-ZaI or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, W, U, X, Y, Z, Ua, Xa, Ya, and Za are defined in the present specification, which are useful as inhibitors of TNF-? converting enzyme (TACE), matrix metalloproteinases (MMP), aggrecanase or a combination thereof.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: September 5, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: Thomas P. Maduskuie
  • Cyclic ?-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-?
    Patent number: 6984648
    Abstract: The present application describes novel cyclic ?-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-? inhibitors.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: January 10, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Zhonghui Lu, Thomas P. Maduskuie, Jr., Matthew E. Voss, Chu-Biao Xue, Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco
  • Benzo-1,4-diazepin-2-ones as inhibitors of A? protein production
    Patent number: 6962913
    Abstract: This invention relates to novel compounds of the class of succinoyl lactams, such as diazepinee of Formula (Id), or a pharmaceutically acceptable salt thereof, as described above, having drug and bio-affecting properties. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of Alzheimer's disease.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: November 8, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
  • Succinoylamino lactams as inhibitors of a&bgr; protein
    Patent number: 6794381
    Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: September 21, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
  • Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20040162426
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: February 13, 2004
    Publication date: August 19, 2004
    Inventors: Zhonghui Lu, Thomas P. Maduskuie, Matthew E. Voss, Chu-Biao Xue, Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco
  • Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
    Publication number: 20040122005
    Abstract: The present application describes novel isoxazoline of formula I or II: 1
    Type: Application
    Filed: October 30, 2003
    Publication date: June 24, 2004
    Inventors: Chu-Biao Xue, Thomas P. Maduskuie, Stephen E. Mercer
  • Cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr;
    Patent number: 6743807
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 1, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco, Zhonghui Lu, Thomas P. Maduskuie, Jr., Chu-Biao Xue
  • Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20040072802
    Abstract: The present application describes novel &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: October 9, 2002
    Publication date: April 15, 2004
    Inventors: Jingwu Duan, Bryan W. King, Carl Decicco, Thomas P. Maduskuie, Mathew E. Voss